| A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in | Freiburg im Breisgau | — | rekrutiert |
| A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multi | Freiburg im Breisgau, Hamburg, Tübingen | Phase III | rekrutiert |
| A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antib | Düsseldorf, Heidelberg, Jena | Phase III | rekrutiert |
| A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple | Hamburg, Leipzig | Phase I / Phase II | rekrutiert |
| A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone | Jena, Lübeck, Chemnitz | Phase III | rekrutiert |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab | Berlin, Essen, Halle (Saale) | Phase III | rekrutiert |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in | Heidelberg, München, Würzburg | Phase I / Phase II | rekrutiert |
| A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary | Dresden, Hamburg, Heidelberg | Phase I / Phase II | rekrutiert |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard | Frankfurt am Main, Hamburg, Karlsruhe | Phase II | rekrutiert |
| A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomi | Tübingen, Ulm, Mainz | Phase III | rekrutiert |
| A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With | Berlin, München | Phase III | rekrutiert |
| A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adu | Greifswald, Lübeck, Würzburg | Phase III | rekrutiert |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple My | Essen, Freiburg im Breisgau, Hamburg | Phase I / Phase II | rekrutiert |
| Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refrac | Hamburg, Chemnitz, Heidelberg | Phase I / Phase II | rekrutiert |
| Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Pa | Heidelberg | ohne Phasenangabe | rekrutiert |
| GMMG Multiple Myeloma Registry | Berlin, Bielefeld, Bochum | — | rekrutiert |
| GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 | Berlin, Chemnitz, Dresden | Phase II | rekrutiert |
| Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multi | Aachen, Augsburg, Bad Saarow | Phase III | rekrutiert |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multi | Freiburg im Breisgau, Stuttgart, Ulm | Phase III | rekrutiert |
| Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | Essen, Mainz, Würzburg | Phase I / Phase II | rekrutiert |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenal | Hamburg, Heidelberg, Jena | Phase III | rekrutiert |
| Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency | Berlin | — | rekrutiert |
| Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available The | Freiburg im Breisgau, Karlsruhe, Chemnitz | Phase III | rekrutiert |
| Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | Berlin, Chemnitz, Köln | Phase I / Phase II | rekrutiert |
| Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squi | Essen | — | rekrutiert |